)
Medexus Pharmaceuticals (MDP) investor relations material
Medexus Pharmaceuticals Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 FY2027 net revenue was $29.100M, up 17.6% YoY; Adjusted EBITDA was $5.1M, operating income $2.440M and net income $0.813M, versus a $0.315M loss.
Q2 revenue, Adjusted EBITDA, operating income and net income were quarterly records since fiscal Q4 2025.
GRAFAPEX achieved record quarterly product-level net revenue of $5.7M, with results described as in line with FY2027 expectations.
Financial highlights
H1 revenue was $57.685M, up 16.9% YoY; growth reflected GRAFAPEX, IXINITY and Rasuvo, partly offset by prior-year royalty revenue.
H1 Adjusted EBITDA increased 25.2% to $9.8M and operating income rose 104.5% to $4.554M, primarily reflecting GRAFAPEX operating leverage.
Q2 gross profit was $16.274M versus $13.786M YoY; SG&A was $13.3M, up 11.6%, mainly due to GRAFAPEX commercialization spending.
Q2 operating cash flow was $5.4M versus $3.3M YoY; H1 operating cash flow was $4.677M versus $7.256M, reflecting higher income taxes and other factors.
H1 net income was $1.357M versus $0.2M; H1 basic and diluted EPS were $0.04 versus $0.01.
Outlook and guidance
FY2027 GRAFAPEX product-level net revenue guidance remains $30M–$32M, requiring acceleration in the remainder of the year through expected adoption and repeat orders.
Long-term GRAFAPEX annual product-level net revenue target is $100M–$175M within five years of launch; long-term product-level Adjusted Gross Margin is expected to reach ~85%.
GRAFAPEX personnel and infrastructure spending is expected at $3M–$4M per quarter through FY2027; additional field-force resources began deployment in Q2.
Meaningful FY2027 operating cash flow is expected as GRAFAPEX scales; working capital may affect quarterly cash flow. Cash and expected operating cash flow are expected to cover operating and capital needs for at least 12 months.
UM171 Cell Therapy commercialization in Canada is not expected before calendar 2028, or potentially 2031 depending on regulatory pathways.
- GRAFAPEX anchors a focused heme-onc strategy, with FY revenue guided at $30M–$32M.MDP
Planet MicroCap Showcase: Toronto 2026 - All agenda items, including director elections and plan amendments, passed unanimously.MDP
AGM 2026 - GRAFAPEX commercialization and a robust rare disease portfolio drive strong US-led revenue growth.MDP
Investor presentation - Record GRAFAPEX growth drove a 16.3% revenue increase and strong Q1 2027 financials.MDP
Q1 2027 - Treosulfan's U.S. launch is set to double revenue and boost margins, driving strong future growth.MDP
Bloom Burton & Co. Healthcare Investor Conference 2025 - GRAFAPEX momentum offsets legacy declines, with FY2027 revenue projected at $30–$32M.MDP
Q4 2026 - GRAFAPEX adoption and margin gains offset portfolio headwinds and support future growth.MDP
Q3 2026 - Q2 revenue fell but net income and EBITDA rose; treosulfan US launch prep underway.MDP
Q2 2025 - Record revenue and EBITDA achieved; key regulatory reviews and leadership changes underway.MDP
Q4 2024
)
)
)
)
)
)
)
)